Department of Endocrinology, Drum Tower Clinical Medical College of Nanjing Medical University, Nanjing, China.
Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China.
J Diabetes Investig. 2018 Jul;9(4):789-798. doi: 10.1111/jdi.12785. Epub 2018 Jan 12.
AIMS/INTRODUCTION: To investigate the prevalence and risk factors of metabolic syndrome (MetS) in Chinese type 2 diabetes mellitus patients, and assess the effect of MetS on the treatment patterns and blood glucose, blood pressure and blood lipids goal achievements.
Data from 25,454 type 2 diabetes mellitus patients including demographic data, anthropometric measurements, treatment patterns, and blood glucose and lipid profiles were retrospectively analyzed.
Using modified Adult Treatment Panel III MetS criteria, the prevalence of MetS was 57.4% in type 2 diabetes mellitus patients. Multivariable logistic regression analysis showed that type 2 diabetes mellitus patients, who also fulfilled the criteria for MetS, tended to be women, living in the northeast, with a diabetes duration ≥5 years and leading a sedentary lifestyle. Most MetS (53.4%) and non-MetS (57%) diabetes patients received oral hypoglycemic drugs. Insulin or insulin combination therapies were more applied in MetS (37.5%) than in non-MetS (33.1%) diabetes patients, and the percentages of MetS diabetes patients receiving antihypertensive and lipid-modulating drugs were 52.9% and 28.2% vs 38.3% and 19.3% of the non-MetS diabetes patients. Just 37.5%, 15.6% and 32.9% of the MetS diabetes patients vs 54.6%, 45.6% and 40.4% of the non-MetS diabetes patients achieved the individual target goals for control of blood glucose (glycosylated hemoglobin <7%), blood pressure (systolic blood pressure <130 mmHg, diastolic blood pressure <80 mmHg) and blood lipids (total cholesterol <4.5 mmol/L), whereas just 2.1% achieved all three target goals.
MetS with a high prevalence in Chinese type 2 diabetes mellitus patients is associated with poor blood glucose, blood pressure and blood lipids control rate.
目的/引言：旨在调查中国 2 型糖尿病患者代谢综合征（MetS）的患病率和危险因素，并评估 MetS 对治疗模式以及血糖、血压和血脂目标达标率的影响。
回顾性分析了 25454 例 2 型糖尿病患者的人口统计学数据、人体测量学指标、治疗模式以及血糖和血脂谱数据。
采用改良的成人治疗小组 III（Adult Treatment Panel III）MetS 标准，2 型糖尿病患者 MetS 的患病率为 57.4%。多变量逻辑回归分析表明，同时符合 MetS 标准的 2 型糖尿病患者更可能为女性、居住在东北地区、糖尿病病程≥5 年且生活方式久坐不动。大多数 MetS（53.4%）和非 MetS（57%）糖尿病患者接受口服降糖药物治疗。MetS（37.5%）患者比非 MetS（33.1%）患者更常使用胰岛素或胰岛素联合治疗，MetS 糖尿病患者接受降压和调脂药物的比例分别为 52.9%和 28.2%，而非 MetS 糖尿病患者的比例分别为 38.3%和 19.3%。MetS 糖尿病患者中仅 37.5%、15.6%和 32.9%分别达到血糖（糖化血红蛋白＜7%）、血压（收缩压＜130mmHg，舒张压＜80mmHg）和血脂（总胆固醇＜4.5mmol/L）的个体控制目标，而非 MetS 糖尿病患者中达到这三个目标的比例分别为 54.6%、45.6%和 40.4%。仅有 2.1%的患者达到了所有三个目标。
中国 2 型糖尿病患者中 MetS 患病率较高，与血糖、血压和血脂控制率差有关。
